Clinical experiences with interferon-alpha and interferon-gamma.
Steinmann
G G
GG
Boehringer Ingelheim, Biberach, Germany.
Rosenkaimer
F
F
Leitz
G
G
D002986:Clinical Trials as Topic; D005334:Fever / Q000139:chemically induced; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006105:Granulomatous Disease, Chronic / Q000628:therapy; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000009:adverse effects / Q000627:therapeutic use*; D009369:Neoplasms / Q000628:therapy*; D009422:Nervous System Diseases / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced; D011994:Recombinant Proteins; D012074:Remission Induction; D012871:Skin Diseases / Q000139:chemically induced
D007155:Immunologic Factors; D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007371:Interferon-gamma